Predicting Fatal Drug Poisoning Among People Living with HIV‑HCV Co‑Infection
Mélanie Bédard, Erica Em Moodie, Joseph Cox, John Gill, Sharon Walmsley, Valérie Martel‑Laferrière, Curtis Cooper, Marina B Klein, Canadian Liver Journal, 2025
Topic
Emergency care
decriminalisation
Harm reduction
Law enforcement/incarceration
Longitudinal polysubstance use patterns and non-fatal overdose: a repeated measures latent class analysis
Karamouzian M, Cui Z, Hayashi K, DeBeck K, Reddon H, Buxton J, Kerr T, Int J Drug Policy
Harnessing telemedicine to deliver patient‑centered opioid agonist treatment within a community‑based harm reduction service: a mixed methods evaluation
Stine Bordier Høj, Rémi Coignard‑Friedman, Aissata Sako, Catherine de Montigny, Marie‑Ève Beauchemin‑Nadeau, Robert Léandre, Nanor Minoyan, Geneviève Boyer‑Legault, Sofiane Chougar, Sara‑Kim Lamont, Julie Bruneau, Harm Reduction Journal , 2025
The Effect of Opioid Agonist Treatment on Injection-Related Sequelae: A Population-Based Observational Study
Lim J, Bruneau J, Platt RW, Panagiotoglou D., Drug Saf. 2025
Impacts of the COVID-19 Pandemic on Opioid Use Disorder and Services for American Indian and Alaska Native Communities
Parker DG, Radin S, Sorlagas N, Wendt DC., Health Res. 2025
Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with Prescription-Type Opioid Use Disorder: Concordance entre le dépistage de drogues dans l’urine et l’usage autodéclaré dans le contexte d’un essai pragmatique contrôlé à répartition aléatoire chez des personnes présentant un trouble lié à l’usage d’opioïdes vendus sur ordonnance
Bastien G, Abboud A, McAnulty C, Mahroug A, Le Foll B, Socias ME, Juteau LC, Dubreucq S, Jutras-Aswad D., Can J Psychiatry. 2025
Opioid agonist treatment
Prescription monitoring
Exploring unregulated substance use health data in Ontario, Canada: Identifying gaps, addressing challenges, and uncovering opportunities
Ali, F., Law, J., Russell, C., Imtiaz, S., Bayoumi, A., Werb, D., Rhem, J., Front. Public Health
A protocol for high-dose lisdexamfetamine and contingency management, alone or in combination, for the treatment of methamphetamine use disorder: The ASCME study
Bach P, Le Foll B, Davidson S, de Kiewit A, Bakouni H, Poulin G, Ghosh M, Jutras-Aswad D., Contemp Clin Trials. 2025
Binge Drug Injection in a Cohort of People Who Inject Drugs in Montreal: Characterizing the Substances and Social Contexts Involved
Nanor Minoyan, Stine Bordier Høj, Didier Jutras‑Aswad, Sarah Larney, Valérie Martel‑Laferrière, Marie‑Pierre Sylvestre, Julie Bruneau, International Journal of Mental Health and Addiction, 2025
Is Naltrexone Effective and Safe for Treating Amphetamine-Type Stimulant Use Disorder? A Systematic Review and Meta-analysis
Bastien G, McAnulty C, Sharafi H, Mahroug A, Elkrief L, Ziegler D, Dubreucq S, Juteau LC, Jutras-Aswad D., J Addict Med. 2025
Illicit drug toxicity from opioid, stimulant or sedative use in adolescents: results of a Canadian one‑time cross‑sectional study
Matthew Carwana, Eva Moore, Helia Shariati, Hasina Samji, Nicholas Chadi, Paediatrics & Child Health, 2025
